Last time I looked there are about 100 plus drug combinations to treat cardiovascular disease not every drug suits every person new technologies will continue to evolve
At the moment no AD treatment provides significant benefits
other than symptomatic relief
PBT2 offers a good prospect but it won't suit everybody
Prana has more MPACs to try and other companies will continue to attack different pathways
Great to have Rudi Tanzi in our corner and if we get 10 years near the top none of us will mind if something better comes along
on the nas this morning, page-19
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $15.96M | |||
| Open | High | Low | Value | Volume |
| 0.3¢ | 0.3¢ | 0.3¢ | $313 | 104.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 51 | 77078609 | 0.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.3¢ | 6164594 | 4 |
View Market Depth
| Last trade - 15.59pm 09/09/2024 (20 minute delay) ? |
| ATH (ASX) Chart |